$5.32
0.081.53%
In chiusura: -
$5.32
0.000.00%
After hour: 4:00 PM EDT
Comments
Loading...
Stime degli utili, EPS e fatturato
Aldeyra Therapeutics segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Data degli utili
nov 6
Stima EPS
$-0.160
Stima dei ricavi trimestrali
$24.25M
Ricavi annuali
(a partire da giu 30)
(a partire da giu 30)
–
Analizza lo storico degli utili di Aldeyra Therapeutics utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
ALDX | Aldeyra Therapeutics | -$0.25 | -$0.16 | — | — | $0.00 | $24.25M | — | — | 11/06/2025 | |
ALDX | Aldeyra Therapeutics | -$0.28 | -$0.17 | -$0.16 | 5.88% | $0.00 | $2.60M | $0.00 | -100.00% | 08/07/2025 | |
ALDX | Aldeyra Therapeutics | -$0.14 | -$0.24 | -$0.17 | 29.17% | $0.00 | — | $0.00 | — | 05/14/2025 | |
ALDX | Aldeyra Therapeutics | -$0.08 | -$0.22 | -$0.27 | -22.73% | $0.00 | — | $0.00 | — | 02/28/2025 | |
ALDX | Aldeyra Therapeutics | -$0.14 | -$0.25 | -$0.25 | 0.00% | $0.00 | — | $0.00 | — | 11/07/2024 | |
ALDX | Aldeyra Therapeutics | -$0.15 | -$0.15 | -$0.28 | -86.67% | $0.00 | — | $0.00 | — | 08/01/2024 | |
ALDX | Aldeyra Therapeutics | -$0.27 | -$0.14 | -$0.14 | 0.00% | $0.00 | — | $0.00 | — | 05/02/2024 | |
ALDX | Aldeyra Therapeutics | -$0.22 | -$0.14 | -$0.08 | 42.86% | $0.00 | $1.86M | $0.00 | -100.00% | 03/07/2024 | |
ALDX | Aldeyra Therapeutics | -$0.25 | -$0.24 | -$0.14 | 41.67% | $0.00 | — | $0.00 | — | 11/03/2023 | |
ALDX | Aldeyra Therapeutics | -$0.30 | -$0.31 | -$0.15 | 51.61% | $0.00 | — | $0.00 | — | 08/03/2023 | |
ALDX | Aldeyra Therapeutics | -$0.29 | -$0.29 | -$0.27 | 6.90% | $0.00 | — | $0.00 | — | 05/04/2023 | |
ALDX | Aldeyra Therapeutics | -$0.27 | -$0.31 | -$0.22 | 29.03% | $0.00 | — | $0.00 | — | 03/09/2023 | |
ALDX | Aldeyra Therapeutics | -$0.27 | -$0.34 | -$0.25 | 26.47% | $0.00 | — | $0.00 | — | 11/10/2022 | |
ALDX | Aldeyra Therapeutics | -$0.28 | -$0.31 | -$0.30 | 3.23% | $0.00 | — | $0.00 | — | 08/05/2022 | |
ALDX | Aldeyra Therapeutics | -$0.25 | -$0.31 | -$0.29 | 6.45% | $0.00 | — | $0.00 | — | 05/05/2022 | |
ALDX | Aldeyra Therapeutics | -$0.30 | -$0.28 | -$0.27 | 3.57% | $0.00 | — | $0.00 | — | 03/17/2022 | |
ALDX | Aldeyra Therapeutics | -$0.23 | -$0.26 | -$0.27 | -3.85% | $0.00 | — | $0.00 | — | 10/28/2021 | |
ALDX | Aldeyra Therapeutics | -$0.25 | -$0.24 | -$0.28 | -16.67% | $0.00 | — | $0.00 | — | 08/05/2021 | |
ALDX | Aldeyra Therapeutics | -$0.34 | -$0.27 | -$0.25 | 7.41% | $0.00 | — | $0.00 | — | 05/06/2021 | |
ALDX | Aldeyra Therapeutics | -$0.47 | -$0.28 | -$0.30 | -7.14% | $0.00 | — | $0.00 | — | 03/11/2021 | |
ALDX | Aldeyra Therapeutics | -$0.69 | -$0.27 | -$0.23 | 14.81% | $0.00 | — | $0.00 | — | 11/05/2020 |
Aldeyra Therapeutics (ALDX) Guadagno per azione
Importo a sorpresa sugli utili trimestrali
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-08-07 | $-0.16 | $-0.17 | 5.88 % |
| Q1 | 2025-05-14 | $-0.17 | $-0.24 | 29.2 % |
| Q4 | 2025-02-28 | $-0.27 | $-0.22 | -22.7 % |
| Q3 | 2024-11-07 | $-0.25 | $-0.25 | 0.00 % |
Aldeyra Therapeutics (ALDX) Entrate
Importo sorpresa sulle entrate trimestrali
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-08-07 | $0 | $2.60M | -100.0 % |
| Q4 | 2024-03-07 | $0 | $1.86M | -100.0 % |
FAQ
Quando Aldeyra Therapeutics (NASDAQ:ALDX) riporterà gli utili?
Si prevede che Aldeyra Therapeutics (ALDX) fornisca risultati il novembre 6, 2025. Gli ultimi risultati sono stati pubblicati il agosto 7, 2025 per il Q2.
Quali sono stati gli ultimi utili per azione (EPS) di Aldeyra Therapeutics (NASDAQ:ALDX)?
L'EPS effettivo era $-0.16, che superato la stima di $-0.17.
Quali sono state le entrate di Aldeyra Therapeutics (NASDAQ:ALDX)?
Le entrate effettive sono state $0K, che mancato la stima di $2.6M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.